Skip to main navigation
logo
  • Overview
  • Corporate
    • Corporate Profile
    • Management
    • Board of Directors
    • Key Advisors
    • Corporate Governance
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Quarterly Results
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • IR Contacts

News & Events

News Releases

News Releases

  • All
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
2022.02.02
Adagene Announces Board and Management Appointments to Support Pipeline Growth
2022.01.27
Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116
2022.01.19
Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.
2022.01.13
Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore
2021.12.22
Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked Antibody-Drug Conjugate Candidates

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Current page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »
Displaying 21 - 25 of 59

Shareholder Tools

  • © 2023 Adagene Inc.

Footer Bottom

  • Home
  • Privacy
  • Terms of Use
  • Contact
  • Site Credits
  • LinkedIn